Childhood acute lymphoblastic leukemia in Turkey: Factors influencing treatment and outcome: A single center experience

Journal of Pediatric Hematology/Oncology

Volumn 32, Issue 8, 2010, Pages e317-e322

  Hazar, Volkan ^a   Karasu, Gulsun Tezcan ^a   Uygun, Vedat ^a   Akcan, Mediha ^a   Küpesiz, Alphan ^a   Yesilipek, Akif ^a  

^a AKDENIZ UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Acute lymphoblastic leukemia; Children; Developing country; Turkey

Indexed keywords

ALL BFM 95 PROTOCOL; ALL-BFM-95 PROTOCOL; ANTINEOPLASTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; MERCAPTOPURINE; PREDNISOLONE; VINCRISTINE; ANTIFUNGAL AGENT; ANTILEUKEMIC AGENT; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CHILD; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; INFANT; MALE; MORTALITY; PRESCHOOL CHILD; PROGNOSIS; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; TURKEY (REPUBLIC); CANCER RADIOTHERAPY; CHILDHOOD LEUKEMIA; CHROMOSOME ANALYSIS; CHRONIC LEUKEMIA; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; IMMUNOPHENOTYPING; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MOLECULAR GENETICS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCHOOL CHILD; TERTIARY HEALTH CARE;

6-MERCAPTOPURINE; ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISOLONE; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TURKEY; VINCRISTINE;

EID: 78349296861     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181ed163c     Document Type: Article

References (18)

1. Möricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008; 111: 4477-4489.
2. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009; 360: 2730-2741.
3. Silverman LB, Stevenson KE, O’Brien JE, et al. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia. 2010; 24: 320-334.
4. Bonilla M, Moreno N, Marina N, et al. Acute lymphobalstic leukemia in a developing country: preliminary results of a nonrandomized clinical trial in El Salvador. J Pediatr Hematol Oncol. 2000; 22: 495-501.
5. Metzger ML, Howard SC, Fu LC, et al. Outcome of childhood acute lymphoblastic leukemia in resource-poor countries. Lancet. 2003; 362: 706-708.
6. Gao Y, Lu F, Wang H. Treating childhood acute lymphoblastic leukemia in a developing country 1998 to 2003: the experience of a single Children’s Hospital in China. J Pediatr Hematol Oncol. 2006; 28: 798-802.
7. Kulkarni KP, Marwaha RK, Trehan A, et al. Survival outcome in childhood ALL: experience from a tertiary care centre in North India. Pediatr Blood Cancer. 2009; 53: 168-173.
8. Bajel A, George B, Mathews V, et al. Treatment of children with acute lymphoblastic leukemia in India using a BFM protocol. Pediatr Blood Cancer. 2008; 51: 621-625.
9. Hussein H, Sidhom I, Naga SA, et al. Outcome and prognostic factors of acute lymphoblastic leukemia in children at the National Cancer Institute, Egypt. J Pediatr Hematol Oncol. 2004; 26: 507-514.
10. Stark B, Nirel R, Avrahami G, et al. Long-term results of the Israeli National Studies in childhood acute lymphoblastic leukemia: INS 84, 89 and 98. Leukemia. 2010; 24: 419-424.
11. Stary J, Jabali Y, Trka J, et al. Prognosis of children with mixed phenotype acute leukemia treated in accordance with consistent immunophenotypic criteria. Leukemia. 2010; 24: 425-428.
12. Pui CH, Pei D, Sandlund JT, et al. Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia. 2010; 24: 371-382.
13. Laosombat V, Wongchanchailert M, Sattayasevana B, et al. The treatment of children with acute lymphoblastic leukemia in Thailand. Med Pediatr Oncol. 2002; 38: 266-268.
14. Magrath I, Shanta V, Advani S, et al. Treatment of acute lymphoblastic leukaemia in countries with limited resources: lessons from use of a single protocol in India over a twenty year period. Eur J Cancer. 2005; 41: 1570-1583.
15. Pui CH, Boyett JM, Rivera GK, et al. Long-term results of total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children’s Research Hospital. Leukemia. 2000; 14: 2286-2294.
16. Eden OB, Harrison G, Richards S, et al. Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980 to 1997. Medical Research Council Childhood Leukaemia Working Party. Leukemia. 2000; 14: 2307-2320.
17. Horibe K, Hara J, Yagi K, et al. Prognostic factors in childhood acute lymphoblastic leukemia in Japan. Japan Association of Childhood Leukemia Study. Int J Hematol. 2000; 72: 61-68.
18. Li CK, Chik KW, Chan GC, et al. Treatment of acute lymphoblastic leukemia in Hong Kong children: HKALL 93 study. Hematol Oncol. 2003; 21: 1-9.